# Implant Pharmacokinetic and Pharmacodynamic Study

> **NCT03634137** · PHASE1 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Afamelanotide Group 1
- **DRUG:** Afamelanotide Group 2

## Key facts

- **NCT ID:** NCT03634137
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634137, "Implant Pharmacokinetic and Pharmacodynamic Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03634137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*